Novavax, Inc. (NVAX)
After hours:
| Previous close | 17.03 |
| Open | 16.76 |
| Bid | 16.51 x 1200 |
| Ask | 16.54 x 900 |
| Day's range | 16.32 - 17.03 |
| 52-week range | 16.00 - 236.50 |
| Volume | |
| Avg. volume | 4,905,371 |
| Market cap | 1.298B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.51 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 78.17 |
- Motley Fool
Is Novavax Stock a Buy Now?
Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.
- Motley Fool
3 Potentially Explosive Stocks to Buy Before 2023
It's been a difficult year for stocks (and investors) in general. But certain stocks have had a particularly trying time. These companies faced specific challenges -- and that's sent their shares tumbling further than the general market.
- Zacks
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
